I’ve been here since 2015, so I feel your pain. Best thing to do, if you can, is average down. I was able to pick up shares in the .40s which lower my overall average significantly. Leronlimab is very promising but the one thing I learned about biotechs is that it takes time to get a drug through trials and approved. Lerlimab will get there, we just have to have patience because even a SP of $5, which is reasonable, will make most a decent profit.